Literature DB >> 8299675

On the question of interindividual variations in chloroquine concentrations.

U Hellgren1, G Alván, M Jerling.   

Abstract

In a review of studies using appropriate methods for drug determinations and controlled intake, an interindividual variation in chloroquine concentrations of 2.3 to 5.6-fold was found. In our department, steady-state concentrations were evaluated in 40 patients with rheumatic diseases. The variation in whole blood concentrations was 11-fold for chloroquine and 10-fold for the desethylchloroquine metabolite. The mean ratio between desethylchloroquine and chloroquine concentrations was 0.53 and the Spearman-Rank correlation 0.92. The correlation between age and the ratio of chloroquine concentration/dose was 0.36 (P < 0.05) and the corresponding correlation for body weight was -0.43 (P < 0.05). Our data indicate that body weight and age are important independent factors for the disposition of chloroquine. However, when extensive 100-fold variations in concentrations are found between individuals we suggest that the reliability of the dose intake should be questioned.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8299675     DOI: 10.1007/BF00265960

Source DB:  PubMed          Journal:  Eur J Clin Pharmacol        ISSN: 0031-6970            Impact factor:   2.953


  10 in total

1.  Response of Plasmodium falciparum to chloroquine treatment: relation to whole blood concentrations of chloroquine and desethylchloroquine.

Authors:  U Hellgren; C M Kihamia; L F Mahikwano; A Björkman; O Eriksson; L Rombo
Journal:  Bull World Health Organ       Date:  1989       Impact factor: 9.408

2.  Concentrations of chloroquine and desethylchloroquine in capillary blood dried on filter paper during and after treatment of Tanzanian children infected with Plasmodium falciparum.

Authors:  L Rombo; C M Kihamia; L F Mahikwano; O Ericsson; F Sjöqvist
Journal:  Trop Med Parasitol       Date:  1986-09

3.  Sensitive method for the determination of chloroquine and its metabolite desethyl-chloroquine in human plasma and urine by high-performance liquid chromatography.

Authors:  Y Bergqvist; M Frisk-Holmberg
Journal:  J Chromatogr       Date:  1980-11-14

Review 4.  Recent developments in the understanding of the pharmacokinetics and mechanism of action of chloroquine.

Authors:  E O Titus
Journal:  Ther Drug Monit       Date:  1989       Impact factor: 3.681

5.  Disposition of chloroquine in man after single intravenous and oral doses.

Authors:  L L Gustafsson; O Walker; G Alván; B Beermann; F Estevez; L Gleisner; B Lindström; F Sjöqvist
Journal:  Br J Clin Pharmacol       Date:  1983-04       Impact factor: 4.335

6.  Distribution of chloroquine and its metabolite desethyl-chloroquine in human blood cells and its implication for the quantitative determination of these compounds in serum and plasma.

Authors:  Y Bergqvist; B Domeij-Nyberg
Journal:  J Chromatogr       Date:  1983-01-14

7.  Comparative bioavailability of rectal and oral formulations of chloroquine.

Authors:  M M Tjoeng; P H Hogeman; H Kapelle; M L De Ridder; H Verhaar
Journal:  Pharm Weekbl Sci       Date:  1991-08-23

8.  Whole blood concentrations of chloroquine and desethylchloroquine during and after treatment of adult patients infected with Plasmodium vivax, P. ovale or P. malariae.

Authors:  L Rombo; A Björkman; E Sego; O Ericsson
Journal:  Trans R Soc Trop Med Hyg       Date:  1986       Impact factor: 2.184

9.  Chloroquine levels in blood during chronic treatment of patients with rheumatoid arthritis.

Authors:  P Augustijns; P Geusens; N Verbeke
Journal:  Eur J Clin Pharmacol       Date:  1992       Impact factor: 2.953

10.  Chloroquine and desethylchloroquine concentrations during regular long-term malaria prophylaxis.

Authors:  L Rombo; Y Bergqvist; U Hellgren
Journal:  Bull World Health Organ       Date:  1987       Impact factor: 9.408

  10 in total
  8 in total

Review 1.  Clinical pharmacokinetics and metabolism of chloroquine. Focus on recent advancements.

Authors:  J Ducharme; R Farinotti
Journal:  Clin Pharmacokinet       Date:  1996-10       Impact factor: 6.447

Review 2.  Pharmacokinetics of quinine, chloroquine and amodiaquine. Clinical implications.

Authors:  S Krishna; N J White
Journal:  Clin Pharmacokinet       Date:  1996-04       Impact factor: 6.447

Review 3.  Application of pharmacogenomics to malaria: a holistic approach for successful chemotherapy.

Authors:  Rajeev K Mehlotra; Cara N Henry-Halldin; Peter A Zimmerman
Journal:  Pharmacogenomics       Date:  2009-03       Impact factor: 2.533

4.  The effect of SNPs in CYP450 in chloroquine/primaquine Plasmodium vivax malaria treatment.

Authors:  Vinicius A Sortica; Juliana D Lindenau; Maristela G Cunha; Maria DO Ohnishi; Ana Maria R Ventura; Ândrea Kc Ribeiro-Dos-Santos; Sidney Eb Santos; Luciano Sp Guimarães; Mara H Hutz
Journal:  Pharmacogenomics       Date:  2016-10-21       Impact factor: 2.533

Review 5.  Pharmacogenomics and COVID-19: clinical implications of human genome interactions with repurposed drugs.

Authors:  Osama A Badary
Journal:  Pharmacogenomics J       Date:  2021-02-04       Impact factor: 3.550

Review 6.  Considerations into pharmacogenomics of COVID-19 pharmacotherapy: Hope, hype and reality.

Authors:  Anmar Al-Taie; Ayşe Şeyma Büyük; Semra Sardas
Journal:  Pulm Pharmacol Ther       Date:  2022-10-18       Impact factor: 3.282

Review 7.  Chloroquine could be used for the treatment of filoviral infections and other viral infections that emerge or emerged from viruses requiring an acidic pH for infectivity.

Authors:  Hephzibah Akpovwa
Journal:  Cell Biochem Funct       Date:  2016-03-21       Impact factor: 3.685

8.  SLCO1A2, SLCO1B1 and SLCO2B1 polymorphisms influences chloroquine and primaquine treatment in Plasmodium vivax malaria.

Authors:  Vinicius A Sortica; Juliana D Lindenau; Maristela G Cunha; Maria Deise O Ohnishi; Ana Maria R Ventura; Ândrea Kc Ribeiro-Dos-Santos; Sidney Eb Santos; Luciano Sp Guimarães; Mara H Hutz
Journal:  Pharmacogenomics       Date:  2017-10-04       Impact factor: 2.533

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.